Prophylaxis Against Venous Thromboembolism in ICU Patients with COVID-19

摘要

Observational data have not yet clarified whether patients with COVID-19 benefit from higher-than-standard-dose prophylaxis for venous thromboembolism (VTE; NEJMJW Gen Med Mar 15 2021 and Thromb Haemost 2021; 121:76). Also, patients with COVID-19 in the intensive care unit (ICU) are more likely to die if major bleeding occurs (NEJMJW Oncol Hematol Feb 2021). Investigators randomized 600 ICU patients (median age, 62) with COVID-19 at 10 Iranian academic medical centers to receive either intermediate-dose (enoxaparin, 1 mg/kg daily) or standard-dose (enoxaparin, 40 mg daily) prophylaxis.